Overview of Dr. Pingali
Dr. Sai Ravi Kiran Pingali is an oncologist in Houston, TX and is affiliated with multiple hospitals in the area, including Houston Methodist Hospital, Houston Methodist Sugar Land Hospital, Houston Methodist Willowbrook Hospital, Houston Methodist Baytown Hospital, Houston Methodist West Hospital, Houston Methodist The Woodlands Hospital, and Houston Methodist Clear Lake Hospital. He received his medical degree from Osmania Medical College NTR UHS and has been in practice 14 years. He is one of 90 doctors at Houston Methodist Hospital and one of 38 doctors at Houston Methodist Clear Lake Hospital who specialize in Oncology. He has more than 40 publications and over 500 citings.
Education & Training
Medical College of Wisconsin Affiliated HospitalsFellowship, Hematology and Medical Oncology, 2010 - 2013
Gundersen Lutheran Medical FoundationResidency, Internal Medicine, 2007 - 2010
Osmania Medical College NTR UHSClass of 2003
Certifications & Licensure
TX State Medical License 2014 - 2025
WI State Medical License 2009 - 2015
American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- Prognostic Effect of Systemic Therapy and Radiation Therapy in Stage I Nodal Marginal Zone Lymphoma.Neil Chevli, Victoria Margolis, Waqar Haque, Sai Ravi Pingali, E Brian Butler
Practical Radiation Oncology. 2022-10-09 - Loss of AID exacerbates the malignant progression of CLL.Avery C Lee, Sai Ravi Pingali, Javier A Pinilla-Ibarz, Michael L Atchison, Constantinos Koumenis
Leukemia. 2022-10-01 - 1 citationsUse of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell ly...Cesar Gentille, Humaira Sarfraz, Jitesh Joshi, Jasleen Randhawa, Shilpan Shah
Cancer Reports. 2022-07-01
Abstracts/Posters
- Primary Cutaneous Anaplastic Large-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis from 2005-2016Sai Ravi Kiran Pingali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Cli...Sai Ravi Kiran Pingali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Grant Support
- Mechanisms of STING in malignant progression and therapy of CLL.METHODIST HOSPITAL RESEARCH INSTITUTE2023–2028
- Mechanisms of STING in malignant progression and therapy of CLL.METHODIST HOSPITAL RESEARCH INSTITUTE2023–2028
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
